Iovance Biotherapeutics, Inc. IOVA Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s investment proceeds?
- Iovance Biotherapeutics, Inc. (IOVA) reported investment proceeds of $74M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s investment proceeds changed year-over-year?
- Iovance Biotherapeutics, Inc.'s investment proceeds decreased by 38.3% year-over-year, from $120M to $74M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s investment proceeds has grown at a -14.9% compound annual growth rate (CAGR), from $762.91M to $400M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.